Neparvis: Uses, Dosage & Side Effects
A sacubitril/valsartan combination (ARNI) for the treatment of chronic heart failure with reduced ejection fraction in adults
Neparvis (sacubitril/valsartan) is a prescription medicine belonging to the angiotensin receptor-neprilysin inhibitor (ARNI) class, used to treat chronic heart failure in adults with reduced ejection fraction (HFrEF). It combines two active substances – sacubitril, which inhibits the enzyme neprilysin to enhance beneficial natriuretic peptides, and valsartan, an angiotensin II receptor blocker (ARB) that counteracts the harmful effects of the renin-angiotensin-aldosterone system. The landmark PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced cardiovascular death by 20% and heart failure hospitalization by 21% compared to enalapril. Neparvis is now recommended as a cornerstone therapy in international heart failure guidelines from the ESC and AHA/ACC.
Quick Facts: Neparvis
Key Takeaways
- Neparvis (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor (ARNI) that provides dual cardiovascular protection by simultaneously enhancing beneficial natriuretic peptide signaling and blocking the harmful effects of angiotensin II.
- The PARADIGM-HF trial demonstrated a 20% reduction in cardiovascular death and a 21% reduction in heart failure hospitalizations compared to enalapril, establishing sacubitril/valsartan as a cornerstone therapy for HFrEF.
- Neparvis must never be combined with ACE inhibitors due to the risk of angioedema; a mandatory 36-hour washout period is required when switching from an ACE inhibitor.
- The recommended starting dose is sacubitril/valsartan 24 mg/26 mg twice daily, with up-titration to the target dose of 97 mg/103 mg twice daily as tolerated over 2–4 weeks.
- Common side effects include hypotension (low blood pressure), hyperkalemia (elevated potassium), and renal impairment, all of which are manageable with monitoring and dose adjustment.
What Is Neparvis and What Is It Used For?
Neparvis is a fixed-dose combination medicine containing two active substances: sacubitril and valsartan. Together they form the first in a new pharmacological class known as angiotensin receptor-neprilysin inhibitors, or ARNIs. This class was developed to address an unmet need in heart failure treatment – the ability to simultaneously enhance the body's protective neurohormonal pathways while blocking the overactivated stress pathways that drive disease progression. Neparvis is available as film-coated tablets in the strength 24 mg sacubitril / 26 mg valsartan (often referred to as Neparvis 50 mg, representing the combined salt complex weight).
Heart failure is a serious chronic condition in which the heart is unable to pump blood efficiently enough to meet the body's metabolic demands. In heart failure with reduced ejection fraction (HFrEF), the left ventricle has a diminished ability to contract and eject blood, typically defined as a left ventricular ejection fraction (LVEF) of 40% or less. HFrEF affects millions of people worldwide and is associated with high rates of hospitalization, significant functional impairment, and reduced life expectancy. Despite advances in treatment over the past decades, heart failure remains one of the leading causes of cardiovascular morbidity and mortality globally.
The development of sacubitril/valsartan represented a paradigm shift in heart failure pharmacotherapy. Prior to its introduction, the backbone of neurohormonal blockade in HFrEF consisted of ACE inhibitors (or ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). While these therapies provided substantial benefits, residual morbidity and mortality remained unacceptably high. Sacubitril/valsartan was designed to provide an additional layer of benefit by targeting the natriuretic peptide system alongside the renin-angiotensin-aldosterone system (RAAS).
Sacubitril is a prodrug that, upon oral administration, is rapidly converted by esterases to the active metabolite LBQ657. LBQ657 is a potent inhibitor of the enzyme neprilysin (also known as neutral endopeptidase or NEP). Neprilysin is responsible for the degradation of several endogenous vasoactive peptides, including atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), bradykinin, substance P, and adrenomedullin. By inhibiting neprilysin, sacubitril increases circulating levels of these beneficial peptides, which promote natriuresis (sodium excretion in urine), diuresis (water excretion), vasodilation, and suppression of aldosterone secretion and sympathetic nervous system activity. These effects collectively reduce cardiac preload and afterload, decrease cardiac fibrosis and hypertrophy, and improve myocardial relaxation.
Valsartan is a well-established angiotensin II type 1 (AT1) receptor blocker. It selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor, sodium-retaining, and growth-promoting effects of angiotensin II on cardiovascular tissue. In the context of neprilysin inhibition, the inclusion of valsartan is pharmacologically critical: neprilysin also degrades angiotensin II, and inhibiting neprilysin alone could paradoxically increase angiotensin II levels, negating any benefit. By combining neprilysin inhibition with AT1 receptor blockade, Neparvis ensures that the harmful effects of any increased angiotensin II are fully blocked while the beneficial effects of enhanced natriuretic peptides are preserved.
The clinical efficacy of sacubitril/valsartan was established by the landmark PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), published in the New England Journal of Medicine in 2014. This was a randomized, double-blind, active-controlled trial involving 8,442 patients with NYHA class II–IV heart failure and an ejection fraction of 40% or less (later amended to 35% or less). Patients were randomized to receive sacubitril/valsartan 97 mg/103 mg twice daily or enalapril 10 mg twice daily, on top of recommended heart failure therapy.
The trial was stopped early due to overwhelming benefit in the sacubitril/valsartan group. Compared with enalapril, sacubitril/valsartan achieved a 20% reduction in cardiovascular death (hazard ratio 0.80; 95% CI 0.71–0.89; p < 0.001), a 21% reduction in heart failure hospitalization (hazard ratio 0.79; 95% CI 0.71–0.89; p < 0.001), and a 16% reduction in all-cause mortality (hazard ratio 0.84; 95% CI 0.76–0.93; p < 0.001). These benefits translated into an estimated additional 1–2 years of life free from cardiovascular death or heart failure hospitalization over the course of the trial. Quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), was also significantly improved.
Based on the PARADIGM-HF results, international guidelines – including the 2021/2023 ESC Guidelines for Heart Failure and the 2022 AHA/ACC/HFSA Guidelines – now recommend sacubitril/valsartan as a first-line replacement for ACE inhibitors or ARBs in patients with HFrEF who remain symptomatic despite optimal medical therapy. In practice, many guidelines now support initiating sacubitril/valsartan as first-line therapy in newly diagnosed HFrEF patients who can tolerate it, rather than first starting an ACE inhibitor and later switching.
What Should You Know Before Taking Neparvis?
Neparvis is a powerful cardiovascular medicine that requires careful patient selection and monitoring. Understanding who should not take this medicine, what precautions are necessary, and how it may affect specific patient groups is essential for safe and effective use. Your prescribing physician will evaluate your complete medical history and current medications before starting Neparvis.
Contraindications
There are several situations in which Neparvis must not be used. These contraindications are absolute and reflect serious safety concerns identified during clinical development and post-marketing surveillance:
- Hypersensitivity: Do not use Neparvis if you are allergic to sacubitril, valsartan, or any of the excipients listed in the tablet formulation.
- Concomitant ACE inhibitor use: Neparvis must never be taken together with any ACE inhibitor (such as enalapril, ramipril, lisinopril, or perindopril). The combination of neprilysin inhibition with ACE inhibition dramatically increases the risk of angioedema, a potentially life-threatening condition involving rapid swelling of the face, tongue, throat, and airway. A mandatory 36-hour washout period after stopping an ACE inhibitor is required before starting Neparvis.
- History of angioedema: Patients who have previously experienced angioedema related to ACE inhibitor or ARB therapy should not receive Neparvis, as they may be at increased risk of recurrence.
- Pregnancy: Neparvis is strictly contraindicated during pregnancy. Drugs acting on the RAAS, including the valsartan component, can cause fetal injury and death when administered during the second and third trimesters. Effects include fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal death.
- Concomitant aliskiren use in diabetic patients: The combination of Neparvis with aliskiren (a direct renin inhibitor) is contraindicated in patients with diabetes mellitus due to the risk of hypotension, hyperkalemia, and renal impairment.
- Severe hepatic impairment: Patients with severe liver disease (Child-Pugh class C) should not receive Neparvis due to lack of clinical experience and the risk of impaired drug metabolism.
If you are currently taking an ACE inhibitor, you must stop it and wait at least 36 hours before taking your first dose of Neparvis. Taking Neparvis with an ACE inhibitor significantly increases the risk of angioedema – a medical emergency involving severe swelling that can obstruct the airway and become life-threatening.
Warnings and Precautions
Even in patients for whom Neparvis is not contraindicated, certain conditions require special caution and close monitoring:
- Hypotension: Neparvis can cause symptomatic low blood pressure, particularly in patients who are volume-depleted (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting). Blood pressure should be corrected before initiating Neparvis, and the starting dose should be reduced in patients at higher risk.
- Hyperkalemia: As with all RAAS inhibitors, Neparvis can increase serum potassium levels. This risk is heightened in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics (spironolactone, eplerenone) or potassium supplements. Regular monitoring of serum potassium is recommended.
- Renal impairment: Neparvis may cause deterioration of kidney function, particularly in patients with pre-existing renal disease, renal artery stenosis, or those receiving concurrent nephrotoxic drugs. Renal function should be monitored regularly, especially during dose titration.
- Angioedema: Although the risk of angioedema with sacubitril/valsartan is low, it can occur. Patients of Black descent may be at higher risk. If angioedema occurs, Neparvis should be immediately discontinued and appropriate emergency treatment administered.
Pregnancy and Breastfeeding
Neparvis is strictly contraindicated during pregnancy. Drugs that act on the RAAS have been shown to cause fetal and neonatal morbidity and mortality when used during the second and third trimesters of pregnancy. Documented adverse fetal effects include hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function, and may result in limb contractures, craniofacial deformation, and pulmonary hypoplasia. Women of childbearing potential should use effective contraception during treatment. If pregnancy is detected, Neparvis should be discontinued as soon as possible.
It is not known whether sacubitril, its active metabolite LBQ657, or valsartan are excreted in human breast milk. Because of the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue breastfeeding or discontinue Neparvis, taking into account the importance of the drug to the mother. In animal studies, sacubitril and its metabolites were detected in the milk of lactating rats.
Effective contraception must be used throughout treatment with Neparvis. If you become pregnant while taking Neparvis, stop the medication immediately and contact your doctor. Exposure to RAAS-acting drugs during the second and third trimesters can cause serious harm to the developing fetus.
How Does Neparvis Interact with Other Drugs?
Because Neparvis acts on multiple neurohormonal pathways and is metabolized through specific hepatic transporters, it has the potential to interact with several classes of medications. Understanding these interactions is essential for avoiding adverse outcomes and optimizing treatment efficacy. Your healthcare provider will review all of your current medications, including over-the-counter drugs, supplements, and herbal products, before prescribing Neparvis.
Major Interactions
The following interactions are considered contraindicated or require extreme caution:
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| ACE inhibitors (enalapril, ramipril, lisinopril) | Dual inhibition of neprilysin and ACE dramatically increases bradykinin levels | Contraindicated – high risk of life-threatening angioedema. 36-hour washout required. |
| Aliskiren | Triple RAAS blockade increases hypotension, hyperkalemia, and renal failure risk | Contraindicated in diabetic patients. Avoid in all patients with eGFR <60 mL/min. |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride) | Additive hyperkalemia risk from combined RAAS blockade and potassium retention | Use with caution. Monitor serum potassium closely, especially with renal impairment. |
| Lithium | RAAS inhibitors decrease lithium renal clearance, increasing plasma levels | Not recommended. If necessary, monitor lithium levels frequently. |
Minor Interactions
The following interactions are generally manageable with monitoring or dose adjustment but should be discussed with your healthcare provider:
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac) | NSAIDs may reduce the antihypertensive and natriuretic effects of Neparvis and worsen renal function | Use with caution. Monitor renal function and blood pressure. |
| Statins (atorvastatin, rosuvastatin) | LBQ657 inhibits OATP1B1 and OATP1B3 hepatic transporters, increasing statin plasma levels by up to 2-fold | Monitor for statin-related side effects (myopathy). Dose adjustment may be needed. |
| Sildenafil / PDE5 inhibitors | Additive blood pressure lowering effect when combined with Neparvis | Monitor blood pressure. Use lower doses of PDE5 inhibitors. |
| Furosemide | Sacubitril/valsartan reduced Cmax and AUC of furosemide by up to 50% and 28% respectively | Clinical significance limited. Monitor diuretic response and adjust dose if needed. |
| Metformin | LBQ657 inhibits metformin transporter (MATE2K), potentially increasing metformin exposure | Monitor renal function in diabetic patients on combination therapy. |
Neparvis does not have clinically significant interactions with digoxin, warfarin, amlodipine, omeprazole, hydrochlorothiazide, or carvedilol. However, as with all cardiovascular medicines, inform your doctor about every medication, supplement, or herbal product you are taking before starting Neparvis.
What Is the Correct Dosage of Neparvis?
Neparvis dosing follows a structured titration approach designed to maximize therapeutic benefit while minimizing the risk of adverse effects, particularly hypotension. The dosing strategy should be individualized based on each patient's blood pressure, renal function, potassium levels, and tolerability. Close medical supervision during the titration phase is essential.
Adults
Standard Titration Schedule
The recommended starting dose is sacubitril/valsartan 24 mg/26 mg twice daily. After 2–4 weeks, if tolerated (systolic blood pressure ≥95 mmHg, no symptomatic hypotension, no hyperkalemia, and stable renal function), the dose should be doubled to 49 mg/51 mg twice daily. After a further 2–4 weeks, the dose is increased to the target maintenance dose of 97 mg/103 mg twice daily.
| Titration Step | Dose (Sacubitril/Valsartan) | Frequency | Duration Before Increase |
|---|---|---|---|
| Starting dose | 24 mg / 26 mg | Twice daily | 2–4 weeks |
| Intermediate dose | 49 mg / 51 mg | Twice daily | 2–4 weeks |
| Target maintenance dose | 97 mg / 103 mg | Twice daily | Long-term |
Patients who are not currently taking an ACE inhibitor or ARB, or who are taking low doses of these agents, should start at the lowest dose (24 mg/26 mg twice daily). Patients who are tolerating moderate to high doses of an ACE inhibitor (equivalent to enalapril 10 mg twice daily) or ARB (equivalent to valsartan 160 mg twice daily) may be started at the intermediate dose (49 mg/51 mg twice daily), provided that they have been off their ACE inhibitor for at least 36 hours.
Neparvis can be taken with or without food. The tablets should be swallowed whole with water and should not be split, crushed, or chewed.
Children
The safety and efficacy of Neparvis in children and adolescents below 18 years of age have not been established for all indications. Pediatric heart failure is an area of active clinical investigation. Sacubitril/valsartan has received approval for use in some pediatric populations (typically children aged 1 year and older with symptomatic systolic heart failure) in certain regulatory jurisdictions, with weight-based dosing. The prescribing physician will determine appropriate use based on current regulatory approvals and clinical guidelines in the relevant country.
Elderly
No dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have impaired renal function, lower baseline blood pressure, and increased susceptibility to hypotension. Therefore, careful monitoring during titration is particularly important in patients over 75 years of age. The starting dose of 24 mg/26 mg twice daily is recommended, with slow titration based on tolerability.
Missed Dose
If you miss a dose of Neparvis, take it as soon as you remember, provided it is not close to the time of your next scheduled dose. If it is nearly time for the next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. If you frequently forget doses, consider setting a daily reminder or using a pill organizer.
Overdose
Limited data are available regarding overdose with Neparvis. The most likely manifestations of overdose would be hypotension (very low blood pressure) due to the blood pressure-lowering effects of both sacubitril and valsartan. In case of symptomatic hypotension, supportive treatment should be initiated, including intravenous fluids and vasopressors if necessary. Neparvis is unlikely to be removed by hemodialysis due to the high protein binding of both sacubitril (94%) and valsartan (97%). If overdose is suspected, contact your local poison control center or seek emergency medical attention immediately.
If you suspect an overdose of Neparvis, seek emergency medical attention immediately. Symptoms may include severe dizziness, lightheadedness, fainting, or dangerously low blood pressure. Supportive care with intravenous fluids is the primary treatment.
What Are the Side Effects of Neparvis?
Like all medicines, Neparvis can cause side effects, although not everybody gets them. The side effects observed with sacubitril/valsartan are largely predictable based on its pharmacological mechanism of action – primarily related to blood pressure lowering and effects on renal function and electrolyte balance. Understanding the frequency and nature of these side effects allows patients and healthcare providers to monitor for them proactively and manage them effectively.
In clinical trials, particularly the PARADIGM-HF study, sacubitril/valsartan was generally well tolerated. Importantly, the incidence of several troublesome side effects was actually lower with sacubitril/valsartan than with enalapril, including cough, hyperkalemia requiring discontinuation, and renal impairment requiring discontinuation. The overall rate of study drug discontinuation due to adverse events was lower in the sacubitril/valsartan group compared with the enalapril group.
Very Common
Affects more than 1 in 10 patients
- Hypotension (low blood pressure) – reported in approximately 18% of patients in clinical trials, making it the most frequently observed adverse effect
- Hyperkalemia (elevated blood potassium levels) – observed in approximately 12% of patients, though levels requiring treatment discontinuation were uncommon
- Renal impairment (decreased kidney function) – including increases in serum creatinine, typically mild and reversible with dose adjustment
Common
Affects 1 in 10 to 1 in 100 patients
- Dizziness – often related to blood pressure lowering, especially during initial titration or when standing up quickly
- Cough – less frequent than with ACE inhibitors; occurred in approximately 9% of patients (vs. 13% with enalapril)
- Fatigue and asthenia (weakness)
- Nausea and diarrhea
- Anemia (decreased hemoglobin levels)
- Syncope (fainting) – related to hypotension, particularly in the initial weeks of treatment
- Orthostatic hypotension (drop in blood pressure upon standing)
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Angioedema (swelling of the face, lips, tongue, or throat) – reported in 0.5% of patients, compared to 0.2% with enalapril
- Pruritus (itching)
- Rash
- Acute renal failure
Rare
Affects fewer than 1 in 1,000 patients
- Severe hypersensitivity reactions
- Stevens-Johnson syndrome (very rare, isolated reports)
- Hepatic function abnormalities
Most side effects of Neparvis are dose-dependent and occur predominantly during the initial titration phase. Many patients find that side effects diminish over time as the body adjusts to the medication. If you experience persistent dizziness or lightheadedness, your doctor may temporarily reduce the dose or adjust your other heart failure medications (particularly diuretics) before attempting to re-titrate.
It is important to attend all scheduled follow-up appointments so that your healthcare provider can monitor your blood pressure, kidney function, and potassium levels. Blood tests are typically performed at 1–2 weeks after each dose increase, then periodically during long-term treatment. Report any unusual symptoms to your doctor promptly, particularly swelling of the face or difficulty breathing, which may indicate angioedema.
Contact your doctor or seek emergency care immediately if you experience: sudden swelling of the face, lips, tongue, or throat (angioedema); difficulty breathing or swallowing; severe dizziness or fainting; very rapid or irregular heartbeat; significantly reduced urine output; or unexplained muscle weakness or cramps (which may indicate dangerously high potassium levels).
How Should You Store Neparvis?
Proper storage of Neparvis ensures that the medication retains its full potency and safety throughout its shelf life. Like many cardiovascular medications, sacubitril/valsartan is sensitive to environmental conditions, and improper storage can compromise the stability of the active ingredients and potentially reduce the effectiveness of treatment.
Neparvis film-coated tablets should be stored at temperatures below 25°C (77°F). Keep the tablets in their original blister packaging or container to protect them from moisture, as sacubitril can be hygroscopic (absorbs moisture from the air). Do not transfer the tablets to a different container unless it provides equivalent moisture protection.
Store Neparvis in a dry location away from direct sunlight, heat, and humidity. The bathroom medicine cabinet is generally not recommended for storage due to the high humidity environment. A bedroom drawer or kitchen cupboard (away from the stove and sink) at normal room temperature is preferable.
Do not use Neparvis after the expiry date printed on the packaging. The expiry date refers to the last day of that month. Do not dispose of Neparvis in household waste or via wastewater. Ask your pharmacist about local medication disposal programs to help protect the environment.
Keep Neparvis out of the sight and reach of children. If you use a pill organizer, ensure it is stored in an appropriate location. If a tablet appears discolored, crumbled, or damaged, do not take it – dispose of it properly and take a new tablet from the package.
What Does Neparvis Contain?
Neparvis tablets contain a fixed-dose combination of two active substances delivered as the sacubitril valsartan sodium salt complex. This molecular complex ensures that both active ingredients are released simultaneously upon oral administration. The 24 mg/26 mg strength provides sacubitril 24.3 mg and valsartan 25.7 mg (equivalent to approximately 50 mg of the combined salt complex).
The active substances work together synergistically:
- Sacubitril (24.3 mg): A prodrug that is converted to the active neprilysin inhibitor LBQ657. Neprilysin inhibition increases circulating levels of natriuretic peptides (ANP, BNP, CNP), bradykinin, and other vasoactive peptides that promote beneficial cardiovascular effects including vasodilation, natriuresis, and reduction of cardiac fibrosis.
- Valsartan (25.7 mg): A selective angiotensin II type 1 (AT1) receptor blocker that prevents the binding of angiotensin II. This blocks vasoconstriction, aldosterone secretion, sympathetic activation, and cardiac remodeling driven by the overactivated RAAS in heart failure.
The film-coated tablets also contain the following inactive ingredients (excipients), which serve various pharmaceutical functions:
- Tablet core: Microcrystalline cellulose (filler/binder), hydroxypropylcellulose (binder), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), talc (glidant), colloidal anhydrous silica (glidant).
- Film coating: Hypromellose (film former), titanium dioxide E171 (opacifier), macrogol 4000 (plasticizer), talc (anti-tacking), iron oxide red E172 (colorant for certain strengths), iron oxide yellow E172 (colorant for certain strengths), iron oxide black E172 (colorant for certain strengths).
If you have known allergies to any excipients, review the full ingredient list with your pharmacist before starting treatment. Patients with rare hereditary problems of galactose intolerance should be aware that some formulations may contain lactose, though the Neparvis formulation uses cellulose-based fillers instead.
Frequently Asked Questions About Neparvis
Neparvis (sacubitril/valsartan) is used to treat chronic heart failure in adults, primarily in patients with reduced ejection fraction (HFrEF), where the heart's pumping ability is weakened. It reduces the risk of cardiovascular death and hospitalization for heart failure. In the landmark PARADIGM-HF trial, sacubitril/valsartan demonstrated a 20% reduction in cardiovascular death and 21% reduction in heart failure hospitalization compared to the ACE inhibitor enalapril. Neparvis is typically prescribed as part of a comprehensive treatment regimen that may also include beta-blockers, mineralocorticoid receptor antagonists, and diuretics.
Unlike ACE inhibitors (which block the conversion of angiotensin I to angiotensin II) or ARBs (which block the angiotensin II receptor), Neparvis provides a dual mechanism of action. The sacubitril component inhibits neprilysin, an enzyme that breaks down beneficial natriuretic peptides, thereby enhancing vasodilation, sodium excretion, and anti-fibrotic effects. The valsartan component provides ARB-mediated blockade of the RAAS. This dual approach simultaneously boosts protective pathways and suppresses harmful ones, providing greater cardiovascular benefit than either mechanism alone.
No, absolutely not. Taking Neparvis together with an ACE inhibitor is strictly contraindicated because the combination dramatically increases the risk of angioedema – a potentially life-threatening condition involving severe swelling of the face, throat, and airway. When switching from an ACE inhibitor to Neparvis, you must stop the ACE inhibitor and wait at least 36 hours before taking the first dose of Neparvis. Your doctor will guide you through this transition safely.
Hypotension (low blood pressure) is the most common side effect of Neparvis. If you experience symptoms such as dizziness, lightheadedness, or feeling faint, sit or lie down and contact your doctor. Do not stop Neparvis abruptly without medical advice. Your doctor may temporarily reduce the dose of Neparvis or adjust other medications (such as diuretics) that also lower blood pressure. Staying well hydrated and rising slowly from sitting or lying positions can help minimize symptoms. In most cases, blood pressure stabilizes as your body adjusts to the medication.
Neparvis begins to lower blood pressure and reduce cardiac neurohormonal stress within hours of the first dose. However, the full clinical benefits – including reduced risk of hospitalization and improved survival – develop over weeks to months of continued treatment. In the PARADIGM-HF trial, the benefit of sacubitril/valsartan over enalapril was evident within the first few months, with the survival curves continuing to diverge over the study period. Many patients notice improvements in symptoms such as breathlessness and exercise tolerance within the first few weeks of treatment.
Neparvis and Entresto both contain the same active substance combination: sacubitril/valsartan. Entresto is the original brand name developed by Novartis, while Neparvis is another brand name for the same drug substance. Both contain the sacubitril valsartan sodium salt complex and are available in the same dose strengths. They are therapeutically equivalent and used for the same indications. Your doctor or pharmacist may prescribe either brand depending on local availability and formulary preferences.
References
- McMurray JJV, Packer M, Desai AS, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063
- European Medicines Agency. Sacubitril/Valsartan – Summary of Product Characteristics. EMA. Updated 2025.
- U.S. Food and Drug Administration. Entresto (sacubitril/valsartan) – Prescribing Information. FDA. Updated 2024.
- Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure (PIONEER-HF). N Engl J Med. 2019;380(6):539–548. doi:10.1056/NEJMoa1812851
- Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (PARAGON-HF). N Engl J Med. 2019;381(17):1609–1620. doi:10.1056/NEJMoa1908655
- Packer M, Claggett B, Lefkowitz MP, et al. Effect of Neprilysin Inhibition on Renal Function in Patients With Type 2 Diabetes and Chronic Heart Failure. Circulation. 2018;137(14):1397–1405. doi:10.1161/CIRCULATIONAHA.117.032222
- World Health Organization. Model List of Essential Medicines. 23rd edition. WHO; 2023.
Medical Editorial Team
iMedic Medical Editorial Team
Specialists in Cardiology and Clinical Pharmacology
iMedic Medical Review Board
Independent review panel following ESC, AHA/ACC, and WHO guidelines
All content is evidence-based, peer-reviewed, and aligned with the latest international clinical guidelines. Our editorial process follows the GRADE framework for evidence evaluation. iMedic receives no commercial funding and has no affiliation with pharmaceutical companies.